Skip to content

Search

Australia a key contributor to global commitment to end deadly rheumatic heart disease

The World Health Organisation resolution for global action to tackle rheumatic heart disease (RHD) will have significant implications for Australia, which has some of the highest rates of the disease in the world.

Skin infections send eight out of every 100 Aboriginal babies to hospital

In a WA first, researchers from The Kids Research Institute Australia have shown that Aboriginal babies are 22.5 times more likely to be treated for skin infections than non-Aboriginal babies.

Bold bid to end rheumatic heart disease

Some of the nation’s leading medical researchers will converge on Darwin this week to step out a plan to wipe out rheumatic heart disease.

Call for Group A streptococcal infections to become notifiable diseases

Researchers at The Kids Research Institute Australia say Group A Streptococcus should become a nationally notifiable disease in Australia.

Rheumatic Heart Disease Endgame Strategy: what does it mean to community?

Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).

Visit from On Track Watch Community Researchers helps build a pathway of looking at two different cultures

For Aboriginal Community Researchers Minitja Marawili and Yunutju Gondarra, the work of the END RHD CRE is deeply personal.

Laqueisha's story: living with RHD

Laqueisha was just five years old when she was diagnosed with rheumatic heart disease and sent on a 5,000km return trip to Perth for major heart surgery.

First Nations Health and Equity

Aboriginal health is everyone's business. The needs of Aboriginal and Torres Strait Islander families and kids is integrated into all relevant areas of our work. Improving the health and wellbeing of Aboriginal and Torres Strait Islander kids and families is an overarching priority for every team at The Kids.

Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysis

Fear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.